Genprex

Monthly Archives: September 2019

5 Things to Know about Lung Cancer Treatment

Cancer is a complex disease that can be difficult treat. Lung cancer specifically is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, kidney, liver or prostate cancers.

Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is researching and developing therapies for the treatment of lung cancer….

Read More

A Deeper Dive into the Nature Research Scientific Report on TUSC2 and Triple-Negative Breast Cancer

Genprex recently announced that independent researchers found that company’s TUSC2 (tumor suppressor candidate 2) prevented tumor growth in triple-negative breast cancer (TNBC). These independent researchers have no affiliation with Genprex.

Genprex takes a deeper dive into the data of the study to provide analysis and a better understanding of what the study found and what it means for TUSC2….

Read More

Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019

AUSTIN, Texas & CAMBRIDGE, Mass.— (September 18, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will present at the Singular Research Midwestern Values Conference on September 19, 2019 via webcast.

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s webcast presentation. …

Read More

Genprex is Defining a New Immunogene Therapy that Could Change the Course of Cancer

Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.

Gene therapies and immunotherapies are two different types of treatment….

Read More

Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

A direct target of miR-138, TUSC2 mimics miR-138 knockdown

AUSTIN, Texas & CAMBRIDGE, Mass.— (September 11, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options….

Read More

Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference

AUSTIN, Texas & CAMBRIDGE, Mass.— (September 5, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will present at the H.C. Wainwright 21stAnnual Global Investment Conference on September 9, 2019 in New York City.

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be available for one-on-one meetings. …

Read More

Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck

AUSTIN, Texas & CAMBRIDGE, Mass.— (September 3, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market.

These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found on the company’s website….

Read More